Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,708.00
  • Today's Change-51.00 / -2.90%
  • Shares traded24.67k
  • 1 Year change-4.10%
  • Beta0.5643
Data delayed at least 20 minutes, as of Jul 24 2017 15:15 BST.
More ▼

Key statistics

As of last trade Genus PLC (GNS:LSE) traded at 1,708.00, 2.17% above its 52-week low of 1,671.72, set on Apr 03, 2017.
52-week range
Today
1,671.72Apr 03 20172,113.00Oct 05 2016
Markit short selling activity
Low
Med
High
Open1,756.00
High1,759.00
Low1,699.00
Bid1,705.00
Offer1,707.00
Previous close1,759.00
Average volume54.26k
Shares outstanding61.16m
Free float60.78m
P/E (TTM)23.05
Market cap1.08bn GBP
EPS (TTM)0.7631
GBP
Annual div (ADY)22.10
GBX
Annual div yield (ADY)1.26%
Div ex-dateMar 02 2017
Div pay-dateMar 31 2017
Data delayed at least 20 minutes, as of Jul 24 2017 15:15 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Genus PLC shares was Hold at 1,773.00 on 24 Feb 2017Read the full article

Board of Directors

1/8

Bob Lawson, Non-Executive Chairman

2/8

Karim Bitar, Chief Executive

3/8

Stephen Wilson, Group Finance Director

4/8

Nigel Turner, Senior Non-Executive Director

5/8

Lysanne Gray, Non-Executive Director

6/8

Prof.Duncan Maskell, Non-Executive Director

7/8

Lykele van der Broek, Non-Executive Director

8/8

Dan Hartley, Group General Counsel and Company Secretary

Investor Relations Contact

Registered Office:

Genus plc

Matrix House

Basing View

Basingstoke

Hampshire

RG21 4DZ

Registered number: 2972325

Telephone: +44(0)1256 347100

Fax: +44 (0)1256 477385


© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.